MedTrace Logo

Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease

NCT05579236 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-05-07

No results posted yet for this study

Summary

The aim of this study is to find out whether a new image analysis technique called Cortical Disarray Measurement (CDM) could be used to help better diagnose Alzheimer's disease. This study will see whether changes on CDM can be used to identify Alzheimer's disease from a group of people living with memory and thinking problems. The study will also explore how CDM relates to changes in memory or thinking over time.

Conditions

Sponsors & Collaborators

  • University of Southampton

    collaborator OTHER

  • Oxford Brain Diagnostics Ltd

    collaborator UNKNOWN

  • Cardiff and Vale University Health Board

    collaborator OTHER_GOV

  • Cardiff University

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • Bournemouth University

    collaborator OTHER

  • University Hospital Southampton NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Christopher Kipps, PhD · University Hospital Southampton NHS Foundation Trust

  • Steven Chance, PhD · Oxford Brain Diagnostics Ltd

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-28
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05579236 on ClinicalTrials.gov